KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Inventory (2016 - 2025)

Astrazeneca has reported Inventory over the past 11 years, most recently at $6.6 billion for Q4 2025.

  • Quarterly results put Inventory at $6.6 billion for Q4 2025, up 24.0% from a year ago — trailing twelve months through Dec 2025 was $6.6 billion (up 24.0% YoY), and the annual figure for FY2025 was $6.6 billion, up 24.0%.
  • Inventory for Q4 2025 was $6.6 billion at Astrazeneca, up from $5.3 billion in the prior quarter.
  • Over the last five years, Inventory for AZN hit a ceiling of $9.0 billion in Q4 2021 and a floor of $4.7 billion in Q4 2022.
  • Median Inventory over the past 5 years was $5.4 billion (2023), compared with a mean of $6.2 billion.
  • Biggest five-year swings in Inventory: surged 123.24% in 2021 and later plummeted 47.69% in 2022.
  • Astrazeneca's Inventory stood at $9.0 billion in 2021, then plummeted by 47.69% to $4.7 billion in 2022, then increased by 15.43% to $5.4 billion in 2023, then fell by 2.51% to $5.3 billion in 2024, then rose by 24.0% to $6.6 billion in 2025.
  • The last three reported values for Inventory were $6.6 billion (Q4 2025), $5.3 billion (Q4 2024), and $5.4 billion (Q4 2023) per Business Quant data.